Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Landiolol Hydrochloride

FDA-approved product (powder, intravenous), marketed as Rapiblyk.

Registered studies
6
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Landiolol Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrial fibrillation
  • Atrial flutter
  • Supraventricular tachycardia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta blocking agents, selective
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Landiolol Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Landiolol Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery

    NCT05084118 · start 2021-10-21

    Registered record
    Registry ID
    NCT05084118
    Conditions
    Atrial Fibrillation; Postoperative Complications
    Interventions
    Landiolol HCl; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-10-21
    Completion
    2024-06-01
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Postoperative Complications
    InterventionLandiolol HCl; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery

    NCT04607122 · start 2021-01-27

    Registered record
    Registry ID
    NCT04607122
    Conditions
    Atrial Fibrillation; Cardiac Surgery
    Interventions
    Landiolol; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-01-27
    Completion
    2023-07-22
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Cardiac Surgery
    InterventionLandiolol; Saline
    PhasePhase 3
    Registry statusCompleted

  • Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers

    NCT01741519 · start 2012-12

    Registered record
    Registry ID
    NCT01741519
    Conditions
    Healthy
    Interventions
    LDLL600; Brevibloc
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-12
    Completion
    2013-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLDLL600; Brevibloc
    PhasePhase 1
    Registry statusCompleted

  • Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice CT

    NCT00311038 · start 2006-04

    Registered record
    Registry ID
    NCT00311038
    Conditions
    Coronary Artery Disease
    Interventions
    ONO-1101
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    Not recorded
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionONO-1101
    PhasePhase 2
    Registry statusCompleted

  • Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan

    NCT00212654 · start 2001-06

    Registered record
    Registry ID
    NCT00212654
    Conditions
    Postoperative Supraventricular Tachyarrythmia
    Interventions
    ONO-1101
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2001-06
    Completion
    Not recorded
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Supraventricular Tachyarrythmia
    InterventionONO-1101
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan

    NCT00212680 · start 1996-12

    Registered record
    Registry ID
    NCT00212680
    Conditions
    Postoperative Supraventricular Tachyarrythmia
    Interventions
    ONO-1101
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1996-12
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Supraventricular Tachyarrythmia
    InterventionONO-1101
    PhasePhase 2
    Registry statusCompleted